SEARCH THE HSDL

Advanced search    Help

Searching for terms: EXACT: "Center for Biologics Evaluation and Research (U.S.)"   in: publisher

Set an Alert to get future results

Results  1 - 8 (of 8)          sorted by relevance     sort by date

Clear all search criteria

Only 2/3! You are seeing results from the Public Collection, not the complete Full Collection. Sign in to search everything (see eligibility).

  • Oversight of Gulf Coast Hurricane Recovery: Semiannual Report to Congress, October 1, 2006 - March 31, 2007
    Center for Biologics Evaluation and Research (U.S.)
    2008-08
  • Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines
    Center for Biologics Evaluation and Research (U.S.)
    2007-05
  • Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines
    Center for Biologics Evaluation and Research (U.S.)
    2007-05
  • Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products
    United States. Food and Drug Administration; Center for Biologics Evaluation and Research (U.S.)
    2002-01
  • Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry
    United States. Department of Health and Human Services; United States. Food and Drug Administration; Center for Biologics Evaluation and Research (U.S.)
    2020-04
  • Investigational COVID-19 Convalescent Plasma: Guidance for Industry
    United States. Food and Drug Administration; United States. Department of Health and Human Services; Center for Biologics Evaluation and Research (U.S.)
    2020-04-13
  • Investigational COVID-19 Convalescent Plasma: Guidance for Industry [September 2, 2020]
    United States. Food and Drug Administration; United States. Department of Health and Human Services; Center for Biologics Evaluation and Research (U.S.)
    2020-09-02
  • Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing: Guidance for Industry
    United States. Department of Health and Human Services; United States. Food and Drug Administration; Center for Drug Evaluation and Research (U.S.) . . .
    2020-06
      1